MKI67 and neoplasm: Similarly, OmAd-CM treatment significantly increased immunoreactivity to Ki67 in the GC tumour tissues, but CXCL2 silencing of OmAd significantly suppressed the ability of OmAd to increase Ki67 staining (Fig. 4e, f).